187 related articles for article (PubMed ID: 20103744)
21. Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms.
Bonuccelli S; Muscelli E; Gastaldelli A; Barsotti E; Astiarraga BD; Holst JJ; Mari A; Ferrannini E
Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E532-7. PubMed ID: 19531643
[TBL] [Abstract][Full Text] [Related]
22. Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects.
Westberg-Rasmussen S; Starup-Linde J; Hermansen K; Holst JJ; Hartmann B; Vestergaard P; Gregersen S
Bone; 2017 Apr; 97():261-266. PubMed ID: 28126633
[TBL] [Abstract][Full Text] [Related]
23. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Madsbad S; Holst JJ; Krarup T
Diabetologia; 2007 Apr; 50(4):797-805. PubMed ID: 17225124
[TBL] [Abstract][Full Text] [Related]
24. Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.
Bagger JI; Knop FK; Lund A; Holst JJ; Vilsbøll T
Diabetologia; 2014 Aug; 57(8):1720-5. PubMed ID: 24879388
[TBL] [Abstract][Full Text] [Related]
25. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
[TBL] [Abstract][Full Text] [Related]
26. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.
Lanng S; Thorsteinsson B; Røder ME; Orskov C; Holst JJ; Nerup J; Koch C
Acta Endocrinol (Copenh); 1993 Mar; 128(3):207-14. PubMed ID: 8480468
[TBL] [Abstract][Full Text] [Related]
27. Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.
Sherwin RS; Bastl C; Finkelstein FO; Fisher M; Black H; Hendler R; Felig P
J Clin Invest; 1976 Mar; 57(3):722-31. PubMed ID: 1249205
[TBL] [Abstract][Full Text] [Related]
28. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.
Østoft SH; Bagger JI; Hansen T; Pedersen O; Holst JJ; Knop FK; Vilsbøll T
Diabetes; 2014 Aug; 63(8):2838-44. PubMed ID: 24677712
[TBL] [Abstract][Full Text] [Related]
29. Oral glucose has little or no effect on appetite and satiety sensations despite a significant gastrointestinal response.
Lauritsen JV; Bergmann N; Junker AE; Gyldenløve M; Skov L; Gluud LL; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2023 Dec; 189(6):619-626. PubMed ID: 38035766
[TBL] [Abstract][Full Text] [Related]
30. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity.
Salera M; Giacomoni P; Pironi L; Cornia G; Capelli M; Marini A; Benfenati F; Miglioli M; Barbara L
J Clin Endocrinol Metab; 1982 Aug; 55(2):329-36. PubMed ID: 7045154
[TBL] [Abstract][Full Text] [Related]
31. Incretin and glucagon levels in adult offspring exposed to maternal diabetes in pregnancy.
Kelstrup L; Clausen TD; Mathiesen ER; Hansen T; Holst JJ; Damm P
J Clin Endocrinol Metab; 2015 May; 100(5):1967-75. PubMed ID: 25781355
[TBL] [Abstract][Full Text] [Related]
32. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia.
Kramer CK; Borgoño CA; Van Nostrand P; Retnakaran R; Zinman B
Diabetes Care; 2014 Apr; 37(4):1076-82. PubMed ID: 24241790
[TBL] [Abstract][Full Text] [Related]
33. Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion.
Abdul-Ghani M; DeFronzo RA
J Clin Endocrinol Metab; 2007 May; 92(5):1778-84. PubMed ID: 17327375
[TBL] [Abstract][Full Text] [Related]
34. Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose.
Maagensen H; Junker AE; Jørgensen NR; Gluud LL; Knop FK; Vilsbøll T
J Clin Endocrinol Metab; 2018 May; 103(5):2042-2049. PubMed ID: 29506157
[TBL] [Abstract][Full Text] [Related]
35. The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.
Rhee NA; Østoft SH; Holst JJ; Deacon CF; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Sep; 171(3):353-62. PubMed ID: 24935932
[TBL] [Abstract][Full Text] [Related]
36. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.
Meier JJ; Deacon CF; Schmidt WE; Holst JJ; Nauck MA
Diabetologia; 2007 Apr; 50(4):806-13. PubMed ID: 17334652
[TBL] [Abstract][Full Text] [Related]
37. Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis.
Junker AE; Gluud LL; Holst JJ; Knop FK; Vilsbøll T
J Gastroenterol Hepatol; 2015 Oct; 30(10):1522-8. PubMed ID: 25867498
[TBL] [Abstract][Full Text] [Related]
38. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes.
Raskin P; Unger RH
N Engl J Med; 1978 Aug; 299(9):433-6. PubMed ID: 683275
[TBL] [Abstract][Full Text] [Related]
39. Differential Impact of Glucose Administered Intravenously and Orally on Circulating miR-375 Levels in Human Subjects.
Yan X; Wang Z; Westberg-Rasmussen S; Tarbier M; Rathjen T; Tattikota SG; Peck BCE; Kanke M; Oxvig C; Frystyk J; Starup-Linde J; Sethupathy P; Friedländer MR; Gregersen S; Poy MN
J Clin Endocrinol Metab; 2017 Oct; 102(10):3749-3755. PubMed ID: 28973164
[TBL] [Abstract][Full Text] [Related]
40. An extended minimal model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect.
Subramanian V; Bagger JI; Harihar V; Holst JJ; Knop FK; Villsbøll T
Am J Physiol Endocrinol Metab; 2024 Feb; 326(2):E182-E205. PubMed ID: 38088864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
